WuXi Biologics Breaks Ground on State-of-the-Art $1.4 Billion CRDMO Facility in Singapore

19 March 2024 | Tuesday | News

The new CRDMO center in Tuas Biomedical Park will enhance global biologics research and manufacturing capabilities, adding significant capacity and creating 1,500 jobs.
Mr. Gan Kim Yong, Minister for Trade and Industry (center) ,  Dr. Chris Chen, CEO of WuXi Biologics (left) ,  Dr. Jimmy Li, CEO of WuXi XDC (right)

Mr. Gan Kim Yong, Minister for Trade and Industry (center) , Dr. Chris Chen, CEO of WuXi Biologics (left) , Dr. Jimmy Li, CEO of WuXi XDC (right)

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has broken ground on its new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore. The center will provide integrated biologics research, development and manufacturing services.



WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion. It will add 120,000L of manufacturing capacity to WuXi Biologics’ global network, and is expected to employ 1,500 staff.


The site will be equipped with WuXi Biologics’ proprietary technical platforms, along with industry-leading technologies such as single-use technology to provide clients with time-and cost-efficient services. In line with WuXi Biologics’ Environmental, Social and Governance strategy, the site will implement sustainable concepts in the design and construction of the center, deploy digital tools and build energy-saving facilities.


Mr. Png Cheong Boon, Chairman of EDB said, “WuXi Biologics Singapore CRDMO center will strengthen Singapore’s biopharmaceutical sector, which comprises global healthcare companies operating best-in-class manufacturing and R&D facilities, complemented by a strong local R&D and start-up ecosystem. This investment will create significant employment opportunities for Singaporeans, and spur collaborations between WuXi Biologics, our R&D institutions and startups to develop innovative therapeutics and novel modalities. Singapore continues to welcome global healthcare players seeking to innovate, manufacture and commercialize end-to-end solutions for clients worldwide.”


Mr.Alvin Tan, JTC’s Assistant Chief Executive Officer for Industry Cluster Group said, “As the master planner and developer for Singapore’s industrial estates, JTC is committed to cultivating a collaborative ecosystem of like-minded partners within our estates to strengthen Singapore’s position as a biomedical sciences hub. We are delighted that WuXi Biologics will be establishing its CRDMO center in Tuas Biomedical Park to be part of our ecosystem.”


Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are excited to enhance our capacity and geographic footprint by building a new CRDMO center in Singapore to serve the growing demands from the global and emerging Asia-Pacific markets. Our Singapore CRDMO center will provide high-quality and more cost-efficient end-to-end CRDMO services near where our clients operate through our Global Dual Sourcing strategy. As we continue to strengthen our global network, elevate our capacity and capabilities, and advance our technology platforms, we are better positioned to accelerate and transform the discovery, development and manufacturing of innovative biologics to enable global clients to bring their breakthrough therapeutics to patients worldwide.”


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in